RT Journal Article
T1 Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013.
A1 Ruiz-Llobet, Anna
A1 Gassiot, Susanna
A1 Sarrate, Edurne
A1 Zubicaray, Josune
A1 Dapena, José Luis
A1 Rives, Susana
A1 Sevilla, Julián
A1 Menárguez López, Ángela
A1 Panesso Romero, Melissa
A1 Montoya, Catalina
A1 Vagace, José Manuel
A1 Molina Hurtado, José Ramón
A1 García-Morín, Marina
A1 García Abós, Miriam
A1 Mendoza Sánchez, María Carmen
A1 Lendínez, Francisco
A1 Palomo Moraleda, Pilar
A1 Tallón, María
A1 González, Berta
A1 Urrutia, Emilia
A1 Serna, José Vicente
A1 Peláez Pleguezuelos, Irene
A1 Martínez Merino, Marta
A1 Ramos Elbal, Eduardo
A1 Orellana, Elena
A1 Benítez Muñoz, Helga
A1 Berrueco, Rubén
K1 acute lymphoblastic leukemia
K1 children
K1 prophylaxis
K1 thrombophilia
K1 thrombosis
AB Symptomatic venous thromboembolism (VTE) is diagnosed in 3%-14% of patients during pediatric acute lymphoblastic leukemia (ALL) therapy. There are well-known risk factors, but the role of others as inherited thrombophilia is still controversial. Prophylaxis with low molecular weight heparin (LMWH) has been described, but its use is not globally accepted. A retrospective multicentric study in ALL patients 1-18 years old following SEHOP-PETHEMA-2013 treatment guideline was performed to evaluate VTE rate, anticoagulant treatment, outcome, risk factors, and safety and usefulness of LMWH administration as primary thromboprophylaxis in children with inherited thrombophilia. A total of 652 patients were included in the study. VTE incidence was 8.7%. Most of the cases occurred during induction therapy associated with central venous catheter. Univariant analysis showed that family history of thrombosis, presence of mediastinal mass, high-risk treatment group, and inherited thrombophilia were statistically significant risk factors. LMWH administration seemed to decrease VTE rate in patients with inherited thrombophilia and those with T-cell ALL phenotype. Most of the VTE cases occurred in patients without inherited thrombophilia, but when it is present, the VTE risk is higher. LMWH administration was useful to decrease VTE in these patients.
YR 2022
FD 2022-03-27
LK http://hdl.handle.net/10668/20003
UL http://hdl.handle.net/10668/20003
LA en
DS RISalud
RD Apr 7, 2025